Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,291 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,291 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $39.40, for a total value of $90,265.40. Following the completion of the transaction, the chief executive officer owned 128,334 shares in the company, valued at $5,056,359.60. This trade represents a 1.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Berndt Modig also recently made the following trade(s):

• On Friday, August 14th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $34.77, for a total value of $79,692.84.

Pharvaris Price Performance

PHVS opened at $38.06 on Wednesday. The company has a market capitalization of $2.49 billion, a PE ratio of -12.48 and a beta of -2.33. Pharvaris N.V. has a fifty-two week low of $20.65 and a fifty-two week high of $43.25. The business has a 50-day moving average of $35.27 and a 200-day moving average of $31.56.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, equities research analysts expect that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Citizens Jmp increased their price target on shares of Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research note on Wednesday, September 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $75.00 price objective on shares of Pharvaris in a research note on Tuesday, September 8th. Wells Fargo & Company upped their price objective on shares of Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Morgan Stanley increased their target price on shares of Pharvaris from $46.00 to $62.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 9th. Finally, Royal Bank Of Canada raised their target price on Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $59.87.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ phase III data showed that once-daily extended-release deucrictibant reduced hereditary angioedema (HAE) attacks by 83%. The results support the company’s plans to pursue regulatory submissions in 2027 and strengthen the investment case for its lead drug candidate. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst expectations have improved, with the consensus price target reportedly raised 20.08% to $59.77. Recent coverage also includes RBC raising its target to $62 and maintaining an outperform rating, while the broader analyst consensus remains “Moderate Buy.” Pharvaris NV consensus price target raised 20.08% to $59.77
• Positive Sentiment: Recent institutional buying—including new positions from BlackRock and increased holdings by Alyeska Investment Group and Seven Fleet Capital—signals growing professional-investor interest in PHVS.
• Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference, giving management another opportunity to discuss deucrictibant and the company’s development and regulatory strategy with institutional investors. The supplied transcript headline does not identify a separate new announcement. Pharvaris Presents at Morgan Stanley Global Healthcare Conference
• Negative Sentiment: Insider selling is a counterweight: CEO Berndt Modig sold 2,291 shares, President Peng Lu sold 15,000 shares, and insider Anne Lesage sold 30,000 shares for approximately $1.15 million. Lu’s sale was specifically described as covering tax withholding tied to vested equity, which reduces—but does not eliminate—the negative signal. Insider Selling: Pharvaris Insider Sells 30,000 Shares

Hedge Funds Weigh In On Pharvaris

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. venBio Partners LLC acquired a new stake in shares of Pharvaris in the second quarter worth $160,569,809. Wellington Management Group LLP grew its stake in Pharvaris by 12.9% in the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after buying an additional 274,034 shares during the last quarter. Commodore Capital LP grew its stake in Pharvaris by 1.6% in the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after buying an additional 29,525 shares during the last quarter. 5AM Venture Management LLC bought a new position in Pharvaris in the 2nd quarter worth $27,581,008. Finally, Seven Fleet Capital Management LP raised its holdings in Pharvaris by 144.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after acquiring an additional 457,804 shares during the period.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.